Alaunos Therapeutics (TCRT) stock price is $2.97, down 5.11% on the day, as of Oct 20, 2026. It has a market cap of $7.34Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap7.34 Mn
P/E-1.83
P/S2,447.91
Div. Yield0.00
Add ratio to table…
About
Alaunos Therapeutics, Inc. is a preclinical stage biopharmaceutical company focused on developing orally administered small molecule therapeutics for obesity and related metabolic disorders. The company's lead candidate ALN1003 is being investigated as a non hormonal non incretin molecule that aims to reduce body weight and improve liver function without relying on hormone based pathways. Prior to its current focus Alaunos Therapeutics was engaged in the development of cell…
Alaunos Therapeutics, Inc. is a preclinical stage biopharmaceutical company focused on developing orally administered small molecule therapeutics for obesity and related metabolic disorders. The company's lead candidate ALN1003 is being investigated as a non hormonal non incretin molecule that aims to reduce body weight and improve liver function without relying on hormone based pathways. Prior to its current focus Alaunos Therapeutics was engaged in the development of cell based therapies for oncology using a TCR T approach but has since discontinued those programs. As of the fiscal year ended December 31 2025 the company reported a net loss of $4.2 million and an accumulated deficit of $924.6 million. It has not generated any product revenue to date and depends on external funding to sustain its research and development activities.
The company currently does not have any commercial products and therefore has not recorded product revenue. Its financial resources are obtained through private placements, public offerings and potential collaborations or licensing agreements. Management expects to continue seeking additional capital to advance the preclinical program and to support general corporate operations until a therapeutic candidate reaches the market. In the interim the company allocates its cash to research activities, contract manufacturing and general administrative expenses.
Alaunos Therapeutics operates in a highly competitive obesity therapeutics market that is projected to reach one hundred fifty billion dollars by twenty thirty. Major pharmaceutical companies such as Novo Nordisk Eli Lilly Amgen Pfizer dominate the space with hormone based therapies including GLP 1 receptor agonists and dual or triple agonists. Emerging biotechs like Viking Therapeutics and Structure Therapeutics are also pursuing novel mechanisms. The company's approach differs by offering an oral small molecule that works through a non hormonal pathway potentially providing an alternative for patients who experience limited efficacy or intolerable side effects from existing treatments. Its focus on associated metabolic conditions such as fatty liver disease further broadens the therapeutic scope beyond simple weight loss. These factors position Alaunos Therapeutics as a distinct player seeking to address unmet needs in a rapidly expanding industry.
The company intends to serve patients suffering from obesity and related metabolic disorders such as metabolic dysfunction associated steatotic liver disease. Its target population includes adults who have not achieved adequate weight loss with current therapies or who cannot tolerate hormone based agents. Alaunos Therapeutics plans to work with healthcare providers to educate them about the potential benefits of an oral non hormonal option and to engage with payers to secure coverage and reimbursement for future therapies. By addressing both the weight reduction and liver health aspects of metabolic disease the company aims to meet the needs of a broad patient base seeking comprehensive disease management.
Sector:HealthcareSector rationaleAlaunos Therapeutics is a biopharmaceutical company developing small molecule therapeutics for obesity and metabolic disorders, specifically its lead candidate ALN1003. Its business model is centered on the discovery and development of medical products for patients, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:PharmaceuticalsPharmaceuticalsPrimaryAlaunos Therapeutics is developing orally administered small molecule therapeutics, specifically its lead candidate ALN1003, for obesity and metabolic disorders. Because it focuses on small-molecule drug discovery and development rather than biologics, it fits the Pharmaceuticals category.Classified using BQ-MICSCIK: 0001107421
Bull & bear
Investment Thesis
▲ Bull case
TCRT, operating through its subsidiary Alaunos Therapeutics, is positioned to benefit from Melinda Lackey's departure to Valion Bio as a sign of strong talent retention and development within the company's legal and operational leadership, indicating that TCRT cultivates high-caliber professionals capable of advancing to senior roles at peer organizations, which reflects well on its internal governance and talent pipeline, suggesting that the company's legal and compliance infrastructure remains robust despite her exit, as her promotion elsewhere underscores the quality of training and experience gained at TCRT, potentially reducing future legal and regulatory risks as the company advances its clinical-stage oncology cell therapy programs.
The fact that TCRT developed a legal executive with deep expertise in clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance implies that the company has invested significantly in building a sophisticated legal and regulatory framework to support its innovative cell therapy pipeline, which is critical for navigating complex FDA pathways, manufacturing scale-up, and partnership negotiations, suggesting that TCRT’s underlying operational readiness may be stronger than market perceptions indicate, especially as it advances its clinical programs in immunology and cellular therapies where regulatory precision is paramount.
TCRT, operating through its subsidiary Alaunos Therapeutics, is positioned to benefit from Melinda Lackey's departure to Valion Bio as a sign of strong talent retention and development within the company's legal and operational leadership, indicating that TCRT cultivates high-caliber professionals capable of advancing to senior roles at peer organizations, which reflects well on its internal governance and talent pipeline, suggesting that the company's legal and compliance infrastructure remains robust despite her exit, as her promotion elsewhere underscores the quality of training and experience gained at TCRT, potentially reducing future legal and regulatory risks as the company advances its clinical-stage oncology cell therapy programs.
The fact that TCRT developed a legal executive with deep expertise in clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance implies that the company has invested significantly in building a sophisticated legal and regulatory framework to support its innovative cell therapy pipeline, which is critical for navigating complex FDA pathways, manufacturing scale-up, and partnership negotiations, suggesting that TCRT’s underlying operational readiness may be stronger than market perceptions indicate, especially as it advances its clinical programs in immunology and cellular therapies where regulatory precision is paramount.
TCRT faces significant risk from the departure of Melinda Lackey, who served as Senior Vice President of Legal & Administration and managed all legal and compliance functions for the company, as her exit creates an immediate leadership vacuum in a highly regulated clinical-stage biopharmaceutical environment where legal missteps can trigger regulatory delays, compliance failures, or adverse outcomes in ongoing clinical trials, particularly given the complexity of oncology cell therapy development and the need for precise regulatory navigation.
TCRT faces significant risk from the departure of Melinda Lackey, who served as Senior Vice President of Legal & Administration and managed all legal and compliance functions for the company, as her exit creates an immediate leadership vacuum in a highly regulated clinical-stage biopharmaceutical environment where legal missteps can trigger regulatory delays, compliance failures, or adverse outcomes in ongoing clinical trials, particularly given the complexity of oncology cell therapy development and the need for precise regulatory navigation.